CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Dietrich, Dimo ^a   Krispin, Manuel ^a   Dietrich, Jörn ^a   Fassbender, Anne ^a   Lewin, Jörn ^a   Harbeck, Nadia ^b   Schmitt, Manfred ^c   Eppenberger Castori, Serenella ^d,e   Vuaroqueaux, Vincent ^d   Spyratos, Frédérique ^f   Foekens, John A ^g   Lesche, Ralf ^a   Martens, John W M ^g  

^a EPIGENOMICS AG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Stiftung Tumorbank Basel   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f CENTRE RENÉ HUGUENIN   (France)

^g JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BISULFITE; CYSTEINE DIOXYGENASE; CYSTEINE DIOXYGENASE 1; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; DISTANT METASTASIS; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENETIC SCREENING; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PROMOTER REGION; QUANTITATIVE STUDY; RETROSPECTIVE STUDY; SCORING SYSTEM; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; CLINICAL TRIAL; ENZYMOLOGY; EUROPE; GENETICS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYSTEINE DIOXYGENASE; DNA METHYLATION; EUROPE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77952804730     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-247     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-49. 10.3322/caac.20006, 19474385.
2. Valero V, Hortobagyi GN. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?. J Clin Oncol 2003, 21:959-62. 10.1200/JCO.2003.11.071, 12637456.
3. Nabholtz JM, Riva A. Taxane/anthracycline combinations: setting a new standard in breast cancer?. Oncologist 2001, 6(Suppl 3):5-12. 10.1634/theoncologist.6-suppl_3-5, 11346678.
4. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C, . Breast Cancer International Research Group 001 Investigators Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352:2302-2313. 10.1056/NEJMoa043681, 15930421, Breast Cancer International Research Group 001 Investigators.
5. Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002, 8:1061-1067.
6. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002, 8:1107-1116.
7. Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegele P, Eber M, Ghnassia JP. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004, 40:205-211. 10.1016/S0959-8049(03)00675-0, 14728934.
8. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006, 5:791-809. 10.1517/14740338.5.6.791, 17044806.
9. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005, 6:597-610. 10.1038/nrg1655, 16136652.
10. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome--components and functional correlates. Genes Dev 2006, 20:3215-3231. 10.1101/gad.1464906, 17158741.
11. Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, Sweep FC, Brunner N, Foekens JA, Schmitt M, . EORTC PathoBiology Group Methylated genes as new cancer biomarkers. Eur J Cancer 2009, 45:335-346. 10.1016/j.ejca.2008.12.008, 19138839, EORTC PathoBiology Group.
12. Dietrich D, Lesche R, Tetzner R, Krispin M, Dietrich J, Haedicke W, Schuster M, Kristiansen G. Analysis of DNA Methylation of Multiple Genes in Microdissected Cells From Formalin-fixed and Paraffin-embedded Tissues. J Histochem Cytochem 2009, 57:477-489. 10.1369/jhc.2009.953026, 2674771, 19153192.
13. Lewin J, Plum A, Hildmann T, Rujan T, Eckhardt F, Liebenberg V, Lofton-Day C, Wasserkort R. Comparative DNA methylation analysis in normal and tumour tissues and in cancer cell lines using differential methylation hybridisation. Int J Biochem Cell Biol 2007, 39:1539-1550. 10.1016/j.biocel.2007.03.006, 17499000.
14. Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A, Niemann S, Foekens JA, Lesche R, Martens JW. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 2009, 15:315-323. 10.1158/1078-0432.CCR-08-0166, 19118060.
15. Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Höfler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005, 65:4101-4117. 10.1158/0008-5472.CAN-05-0064, 15899800.
16. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000, 56:337-344. 10.1111/j.0006-341X.2000.00337.x, 10877287.
17. Satsu H, Terasawa E, Hosokawa Y, Shimizu M. Functional characterization and regulation of the taurine transporter and cysteine dioxygenase in human hepatoblastoma HepG2 cells. Biochem J 2003, 375:441-447. 10.1042/BJ20030535, 1223695, 12871209.
18. Wu QD, Wang JH, Fennessy F, Redmond HP, Bouchier-Hayes D. Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. Am J Physiol 1999, 277:C1229-1238.
19. Condron C, Neary P, Toomey D, Redmond HP, Bouchier-Hayes D. Taurine attenuates calcium-dependent, Fas-mediated neutrophil apoptosis. Shock 2003, 19:564-569. 10.1097/01.shk.0000055814.40894.5f, 12785013.
20. Takatani T, Takahashi K, Uozumi Y, Shikata E, Yamamoto Y, Ito T, Matsuda T, Schaffer SW, Fujio Y, Azuma J. Taurine inhibits apoptosis by preventing formation of the Apaf-1/caspase-9 apoptosome. Am J Physiol 2004, 287:C949-953.
21. Warskulat U, Borsch E, Reinehr R, Heller-Stilb B, Roth C, Witt M, Haussinger D. Taurine deficiency and apoptosis: findings from the taurine transporter knockout mouse. Arch Biochem Biophys 2007, 462:202-209. 10.1016/j.abb.2007.03.022, 17459327.
22. Oien DB, Moskovitz J. Ablation of the mammalian methionine sulfoxide reductase A affects the expression level of cysteine deoxygenase. Biochem Biophys Res Commun 2007, 352:556-559. 10.1016/j.bbrc.2006.11.063, 17126812.
23. Staub E, Gröne J, Mennerich D, Röpcke S, Klamann I, Hinzmann B, Castanos-Velez E, Mann B, Pilarsky C, Brümmendorf T, Weber B, Buhr HJ, Rosenthal A. A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Mol Cancer 2006, 5:37. 10.1186/1476-4598-5-37, 1601966, 16982006.
24. Booken N, Gratchev A, Utikal J, Weiss C, Yu X, Qadoumi M, Schmuth M, Sepp N, Nashan D, Rass K, Tüting T, Assaf C, Dippel E, Stadler R, Klemke CD, Goerdt S. Sezary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia 2008, 22:393-399. 10.1038/sj.leu.2405044, 18033314.
25. Ueki I, Stipanuk MH. Enzymes of the taurine biosynthetic pathway are expressed in rat mammary gland. J Nutr 2007, 137:1887-1894. 2099301, 17634260.
26. Namba R, Maglione JE, Young LJ, Borowsky AD, Cardiff RD, MacLeod CL, Gregg JP. Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ. Mol Cancer Res 2004, 2:453-463.